Shionogi & Co., Ltd.

4507

JP3347200002

Shionogi & Co., Ltd. specializes in development, manufacturing and marketing of pharmaceutical products. The group's activity is organized around 3 families of products: - prescription products: drugs for the treatment of cardiovascular and infectious diseases, diabetes, allergic reactions, etc.; - OTC products: analgesic products, vitamins and tonics, etc.; - diagnosis products: primarily for detection and treatment of cardiovascular diseases and immune system.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q4 2023 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Shionogi & Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7,489 JPY

Average target price

7,782 JPY

Spread / Average Target

+3.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHIONOGI & CO., LTD.	+10.16%	13.62B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-10 am EDT			5-day change	1st Jan Change
7,489 ^JPY	0.00%		+1.97%	+10.16%

Apr. 30	Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	CI
Apr. 25	Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	CI

Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	Apr. 30	CI
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	Apr. 25	CI
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares	Apr. 19	MT
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)	Apr. 18	CI
Shionogi Completes Up to 75 Billion Yen Share Buyback	Mar. 29	MT
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	Mar. 28	CI
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.	Mar. 21	CI
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd.	Mar. 20	CI
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial	Mar. 07	MT
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen	Mar. 06	MT
GSK says ViiV's cabotegravir study supports longer HIV dose interval	Mar. 05	AN
GSK's ViiV Healthcare Says Four-month Interval Between Doses Possible for HIV Treatment Cabotegravir	Mar. 05	MT
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	Mar. 05	CI
US urges court to preserve Obamacare mandate to cover cancer screenings, HIV drugs	Mar. 04	RE
GSK's new HIV drug formula could support longer dosing intervals (March 4)	Mar. 04	RE
GSK Says Data Show For First Time New Ultra Long-Acting Cabotegravir Formulation That Doubles Current Dosing Interval	Mar. 04	RE
US court to weigh Obamacare mandate to cover HIV drug, cancer screenings	Mar. 04	RE
FunPep Company Limited announced that it expects to receive ¥199.9998 million in funding from Shionogi & Co., Ltd.	Mar. 03	CI
Jefferies Adjusts Shionogi’s Price Target to 7,600 Yen From 6,200 Yen, Keeps at Hold	Mar. 01	MT
PureTech notes positive results from Shionogi's EndeavorRx ADHD trial	Feb. 27	AN
Akili, Inc. Announces Positive Results from Shionogi & Co., Ltd. Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx for Pediatric ADHD Patients in Japan	Feb. 27	CI
Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 26	MT
Akili Shares More Than Double After Submission of ADHD Treatment for Marketing Approval in Japan	Feb. 26	MT
Akili's Japan Partner Submits SDT-001 for Marketing Approval in Japan	Feb. 26	DJ
ViiV Says Trial Data Shows Injectable HIV Treatment Cabenuva Has 'Superior Efficacy' Compared With Pills in Some People	Feb. 21	MT